Targeting public neoantigens for cancer immunotherapy,Nature Cancer

当前位置： X-MOL 学术 › Nat. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeting public neoantigens for cancer immunotherapy
Nature Cancer ( IF 23.5 ) Pub Date : 2021-05-17 , DOI: 10.1038/s43018-021-00210-y
Alexander H Pearlman _{1,

2,

3} , Michael S Hwang _{1,

2,

3,

4} , Maximilian F Konig _{1,

2,

3,

5} , Emily Han-Chung Hsiue _{1,

2,

3} , Jacqueline Douglass _{1,

2,

3} , Sarah R DiNapoli _{1,

2,

3} , Brian J Mog _{1,

2,

3,

6} , Chetan Bettegowda _{1,

2,

7,

8} , Drew M Pardoll _{8,

9} , Sandra B Gabelli _{8,

10,

11} , Nicholas Papadopoulos _{1,

2,

9,

12,

13} , Kenneth W Kinzler _{1,

2,

8,

9,

13} , Bert Vogelstein _{1,

2,

3,

8,

9,

12,

13} , Shibin Zhou _{1,

2,

8,

9}

Affiliation

Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Genentech, Inc., South San Francisco, CA, USA.
Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.

中文翻译：

针对癌症免疫治疗的公共新抗原

目前的几种免疫治疗方法针对的是源自个体患者肿瘤特有的突变的私人新抗原。然而，免疫治疗剂也可以针对源自癌症驱动基因反复突变的公共新抗原而开发。后者针对的是肿瘤生长所必需的靶蛋白，并且每种治疗剂都可以应用于众多患者。在这里，我们回顾了确定合适的公共新抗原靶点以及开发针对这些靶点的治疗药物所涉及的机遇和挑战。

更新日期：2021-05-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文